This is a repository copy of Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/109312/

Version: Supplemental Material

Article:
Bell, R, Brown, JM orcid.org/0000-0002-2719-7064, Parmar, M et al. (18 more authors) (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Annals of Oncology, 28 (4). pp. 754-760. ISSN 0923-7534

https://doi.org/10.1093/annonc/mdw665

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in Annals of Oncology following peer review. The version of record, 'Bell, R, Brown, JM, Parmar, M et al (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Annals of Oncology, 28 (4). pp. 754-760,' doi: 10.1093/annonc/mdw665; is available online at: https://doi.org/10.1093/annonc/mdw665.

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
## Supplementary Table S4. Summary of results

<table>
<thead>
<tr>
<th>End point</th>
<th>Primary analysis (cutoff: February 29, 2012)</th>
<th>OS analysis (cutoff: June 30, 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[15]</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy alone</td>
<td>Chemotherapy + bevacizumab</td>
<td>Chemotherapy alone</td>
</tr>
<tr>
<td>(N = 1290)</td>
<td>(N = 1301)</td>
<td>(N = 1290)</td>
</tr>
<tr>
<td>Median duration of follow-up, months</td>
<td>31.5</td>
<td>32.0</td>
</tr>
<tr>
<td>Events, N (%)</td>
<td>205 (15.9)</td>
<td>188 (14.5)</td>
</tr>
<tr>
<td>Stratified HR (95% CI)</td>
<td>0.87 (0.72–1.07)</td>
<td>0.87 (0.73–1.03)</td>
</tr>
<tr>
<td>Log-rank P value</td>
<td>0.18</td>
<td>0.11</td>
</tr>
<tr>
<td>3-year IDFS rate, % (95% CI)</td>
<td>82.7 (80.5–85.0)</td>
<td>83.7 (81.4–86.0)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>OS</td>
<td>Interim</td>
<td>Final</td>
</tr>
<tr>
<td>Events, N (%)</td>
<td>107 (8.3)</td>
<td>93 (7.1)</td>
</tr>
<tr>
<td>Stratified HR (95% CI)</td>
<td>0.84 (0.64–1.12)</td>
<td></td>
</tr>
<tr>
<td>Log-rank P value</td>
<td>0.23</td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; HR, hazard ratio; IDFS, invasive disease-free survival; OS, overall survival.